Literature DB >> 16139925

Cost-of-illness analysis. What room in health economics?

Rosanna Tarricone1.   

Abstract

Cost-of-illness (COI) was the first economic evaluation technique used in the health field. The principal aim was to measure the economic burden of illness to society. Its usefulness as a decision-making tool has however been questioned since its inception. The main criticism came from welfare economists who rejected COIs because they were not grounded in welfare economics theory. Other attacks related to the use of the human capital approach (HCA) to evaluate morbidity and mortality costs since it was said that the HCA had nothing to do with the value people attach to their lives. Finally, objections were made that COI could not be of any help to decision makers and that other forms of economic evaluation (e.g. cost-effectiveness, cost-benefit analysis) would be much more useful to those taking decisions and ranking priorities. Conversely, it is here suggested that COI can be a good economic tool to inform decision makers if it is considered from another perspective. COI is a descriptive study that can provide information to support the political process as well as the management functions at different levels of the healthcare organisations. To do that, the design of the study must be innovative, capable of measuring the true cost to society; to estimate the main cost components and their incidence over total costs; to envisage the different subjects who bear the costs; to identify the actual clinical management of illness; and to explain cost variability. In order to reach these goals, COI need to be designed as observational bottom-up studies.

Entities:  

Mesh:

Year:  2005        PMID: 16139925     DOI: 10.1016/j.healthpol.2005.07.016

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  129 in total

1.  Associations of serious mental illness with earnings: results from the WHO World Mental Health surveys.

Authors:  Daphna Levinson; Matthew D Lakoma; Maria Petukhova; Michael Schoenbaum; Alan M Zaslavsky; Matthias Angermeyer; Guilherme Borges; Ronny Bruffaerts; Giovanni de Girolamo; Ron de Graaf; Oye Gureje; Josep Maria Haro; Chiyi Hu; Aimee N Karam; Norito Kawakami; Sing Lee; Jean-Pierre Lepine; Mark Oakley Browne; Michail Okoliyski; José Posada-Villa; Rajesh Sagar; Maria Carmen Viana; David R Williams; Ronald C Kessler
Journal:  Br J Psychiatry       Date:  2010-08       Impact factor: 9.319

2.  Measuring the externality of antibacterial use from promoting antimicrobial resistance.

Authors:  Klaus Kaier; Uwe Frank
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  The economic burden of atherothrombosis in Greece: results from the THESIS study.

Authors:  Nikos Maniadakis; Georgia Kourlaba; Dennis V Cokkinos; Aggeliki Angeli; John Kyriopoulos
Journal:  Eur J Health Econ       Date:  2012-07-10

Review 4.  Cost-of-Illness Studies: An Updated Review of Current Methods.

Authors:  Eberechukwu Onukwugha; Jacquelyn McRae; Alex Kravetz; Stefan Varga; Rahul Khairnar; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2016-01       Impact factor: 4.981

5.  The impact of BMI on direct costs in children and adolescents: empirical findings for the German Healthcare System based on the KiGGS-study.

Authors:  Christina M Wenig
Journal:  Eur J Health Econ       Date:  2010-09-29

6.  Total economic cost and burden of dengue in Nicaragua: 1996-2010.

Authors:  Zachary S Wettstein; Michael Fleming; Aileen Y Chang; David J Copenhaver; Angela R Wateska; Sarah M Bartsch; Bruce Y Lee; Rajan P Kulkarni
Journal:  Am J Trop Med Hyg       Date:  2012-08-13       Impact factor: 2.345

7.  Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe.

Authors:  Karine Chevreul; Morgane Michel; Karen Berg Brigham; Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Domenica Taruscio; Arrigo Schieppati; Georgi Iskrov; Márta Péntek; Johann Matthias Graf von der Schulenburg; Panos Kanavos; Ulf Persson; Giovani Fattore
Journal:  Eur J Health Econ       Date:  2016-04-08

8.  Cost-of-illness studies: a guide to critical evaluation.

Authors:  Allison Larg; John R Moss
Journal:  Pharmacoeconomics       Date:  2011-08       Impact factor: 4.981

Review 9.  Climate change and allergic disease.

Authors:  Leonard Bielory; Kevin Lyons; Robert Goldberg
Journal:  Curr Allergy Asthma Rep       Date:  2012-12       Impact factor: 4.806

10.  Cost and disease burden of dengue in Cambodia.

Authors:  Julien Beauté; Sirenda Vong
Journal:  BMC Public Health       Date:  2010-08-31       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.